Atara Biotherapeutics Inc. (ATRA) Shares Down 1.5% on Insider Selling
Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded down 1.5% on Tuesday following insider selling activity. The company traded as low as $15.75 and last traded at $15.90, with a volume of 63,613 shares traded. The stock had previously closed at $16.15.
Specifically, CEO Isaac E. Ciechanover sold 4,800 shares of the firm’s stock in a transaction dated Friday, October 14th. The stock was sold at an average price of $15.96, for a total value of $76,608.00. Following the transaction, the chief executive officer now directly owns 549,136 shares of the company’s stock, valued at $8,764,210.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher Haqq sold 1,346 shares of the firm’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $22.32, for a total value of $30,042.72. Following the completion of the transaction, the insider now directly owns 295,294 shares in the company, valued at $6,590,962.08. The disclosure for this sale can be found here. 16.10% of the stock is owned by corporate insiders.
Several research analysts have commented on ATRA shares. Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 22nd. Goldman Sachs Group Inc. lowered Atara Biotherapeutics from a “neutral” rating to a “sell” rating and cut their price objective for the company from $23.00 to $16.00 in a research report on Thursday, September 15th. Citigroup Inc. raised their price objective on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research report on Friday, August 19th. Jefferies Group reissued a “buy” rating and issued a $25.00 price objective on shares of Atara Biotherapeutics in a research report on Sunday, July 10th. Finally, JMP Securities reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Atara Biotherapeutics currently has an average rating of “Hold” and a consensus price target of $26.14.
The firm’s 50 day moving average is $19.42 and its 200 day moving average is $20.21. The firm’s market capitalization is $453.77 million.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.05. Analysts predict that Atara Biotherapeutics Inc. will post ($2.85) EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the stock. Barclays PLC boosted its position in Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock valued at $108,000 after buying an additional 4,600 shares in the last quarter. BlackRock Inc. boosted its position in Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock valued at $137,000 after buying an additional 5,019 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock valued at $148,000 after buying an additional 6,467 shares in the last quarter. Creative Planning bought a new position in Atara Biotherapeutics during the third quarter valued at approximately $213,000. Finally, Franklin Street Advisors Inc. NC bought a new position in Atara Biotherapeutics during the third quarter valued at approximately $214,000. Institutional investors and hedge funds own 75.58% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.